Werewolf Therapeutics Inc
HOWL0.687USD
+0.040+6.22%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
32.47MMarket Cap
LossP/E TTM
More Details of Werewolf Therapeutics Inc Company
Werewolf Therapeutics, Inc. is a biopharmaceutical company engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. It is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. It is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.
Werewolf Therapeutics Inc Info
Ticker SymbolHOWL
Company nameWerewolf Therapeutics Inc
IPO dateApr 30, 2021
CEOHicklin (Daniel J)
Number of employees46
Security typeOrdinary Share
Fiscal year-endApr 30
Address200 Talcott Avenue
CityWATERTOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02472
Phone16179520555
Websitehttps://werewolftx.com/
Ticker SymbolHOWL
IPO dateApr 30, 2021
CEOHicklin (Daniel J)
Company Executives of Werewolf Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Steven Bloom
Mr. Steven Bloom
Chief Business Officer
Chief Business Officer
--
--
Dr. Michael B. Atkins, M.D.
Dr. Michael B. Atkins, M.D.
Independent Director
Independent Director
--
--
Dr. Briggs W. Morrison, M.D.
Dr. Briggs W. Morrison, M.D.
Director
Director
--
--
Dr. Daniel J. (Dan) Hicklin, Ph.D.
Dr. Daniel J. (Dan) Hicklin, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Alon Lazarus, Ph.D.
Dr. Alon Lazarus, Ph.D.
Independent Director
Independent Director
--
--
Dr. Meeta Chatterjee, Ph.D.
Dr. Meeta Chatterjee, Ph.D.
Independent Director
Independent Director
--
--
Dr. Chulani Karunatilake, Ph.D.
Dr. Chulani Karunatilake, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Michael A. (Mike) Sherman
Mr. Michael A. (Mike) Sherman
Independent Director
Independent Director
--
--
Dr. Luke Evnin, Ph.D.
Dr. Luke Evnin, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Randi Isaacs, M.D.
Dr. Randi Isaacs, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Steven Bloom
Mr. Steven Bloom
Chief Business Officer
Chief Business Officer
--
--
Dr. Michael B. Atkins, M.D.
Dr. Michael B. Atkins, M.D.
Independent Director
Independent Director
--
--
Dr. Briggs W. Morrison, M.D.
Dr. Briggs W. Morrison, M.D.
Director
Director
--
--
Dr. Daniel J. (Dan) Hicklin, Ph.D.
Dr. Daniel J. (Dan) Hicklin, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Alon Lazarus, Ph.D.
Dr. Alon Lazarus, Ph.D.
Independent Director
Independent Director
--
--
Dr. Meeta Chatterjee, Ph.D.
Dr. Meeta Chatterjee, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
13.76%
MPM Capital Inc.
9.86%
MPM BioImpact LLC
4.96%
Arkin Bio Ventures LP
4.22%
BofA Global Research (US)
3.77%
Other
63.43%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
13.76%
MPM Capital Inc.
9.86%
MPM BioImpact LLC
4.96%
Arkin Bio Ventures LP
4.22%
BofA Global Research (US)
3.77%
Other
63.43%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
16.20%
Venture Capital
13.76%
Investment Advisor
5.33%
Hedge Fund
4.82%
Research Firm
4.65%
Corporation
4.22%
Individual Investor
1.39%
Other
49.62%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
159
22.47M
48.14%
-11.02M
2025Q2
157
30.29M
67.51%
-6.30M
2025Q1
159
30.37M
68.02%
-6.24M
2024Q4
157
31.11M
69.81%
-7.22M
2024Q3
161
35.12M
80.23%
-3.46M
2024Q2
148
35.04M
80.49%
-1.98M
2024Q1
150
35.07M
81.79%
+2.03M
2023Q4
134
30.53M
84.54%
+2.78M
2023Q3
139
30.67M
86.21%
+2.11M
2023Q2
142
30.83M
86.75%
+2.42M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
6.68M
14.61%
--
--
Jun 30, 2025
MPM Capital Inc.
4.31M
9.42%
--
--
Jun 30, 2025
MPM BioImpact LLC
2.41M
5.27%
--
--
Jun 30, 2025
Arkin Bio Ventures LP
2.05M
4.48%
--
--
Apr 14, 2025
BofA Global Research (US)
2.13M
4.66%
+25.88K
+1.23%
Jun 30, 2025
The Vanguard Group, Inc.
1.30M
2.84%
-211.19K
-13.99%
Jun 30, 2025
Hicklin Daniel J
647.05K
1.42%
--
--
Apr 14, 2025
Sphera Funds Management Ltd.
626.81K
1.37%
--
--
Jun 30, 2025
DC Funds, LP
589.10K
1.29%
--
--
Jun 30, 2025
Renaissance Technologies LLC
316.30K
0.69%
+252.40K
+394.99%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
0%
ProShares Hedge Replication ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
DFA Dimensional US Core Equity Market ETF
0%
Avantis US Small Cap Equity ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
View more
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
DFA Dimensional US Core Equity Market ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Werewolf Therapeutics Inc?
The top five shareholders of Werewolf Therapeutics Inc are:
RA Capital Management, LP holds 6.68M shares, accounting for 14.61% of the total shares.
MPM Capital Inc. holds 4.31M shares, accounting for 9.42% of the total shares.
MPM BioImpact LLC holds 2.41M shares, accounting for 5.27% of the total shares.
Arkin Bio Ventures LP holds 2.05M shares, accounting for 4.48% of the total shares.
BofA Global Research (US) holds 2.13M shares, accounting for 4.66% of the total shares.
RA Capital Management, LP holds 6.68M shares, accounting for 14.61% of the total shares.
MPM Capital Inc. holds 4.31M shares, accounting for 9.42% of the total shares.
MPM BioImpact LLC holds 2.41M shares, accounting for 5.27% of the total shares.
Arkin Bio Ventures LP holds 2.05M shares, accounting for 4.48% of the total shares.
BofA Global Research (US) holds 2.13M shares, accounting for 4.66% of the total shares.
What are the top three shareholder types of Werewolf Therapeutics Inc?
The top three shareholder types of Werewolf Therapeutics Inc are:
RA Capital Management, LP
MPM Capital Inc.
MPM BioImpact LLC
RA Capital Management, LP
MPM Capital Inc.
MPM BioImpact LLC
How many institutions hold shares of Werewolf Therapeutics Inc (HOWL)?
As of 2025Q3, 159 institutions hold shares of Werewolf Therapeutics Inc, with a combined market value of approximately 22.47M, accounting for 48.14% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -19.37%.
What is the biggest source of revenue for Werewolf Therapeutics Inc?
In --, the -- business generated the highest revenue for Werewolf Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
